

Event

## Revvity at AACR 2024

#### Empowering researchers to unlock possibilities in cancer research

The speed of innovation in cancer research has been extraordinary, with novel targeted treatments and immunotherapies showing real promise. However, due to the evolving nature of the disease, therapy resistance remains a huge challenge. To attempt to overcome this challenge , a deep understanding of every tumor and its microenvironment is needed.

Our latest innovations help provide a holistic understanding of those resistance barriers, enabling the development of personalized combinational therapies. By gaining deep insights into disease, we empower you to advance your research toward breakthroughs.

#### Our shared history of innovation

We have a deep-rooted history of helping you accelerate cancer research. Today, our family of innovative products, including the IVIS <sup>®</sup> Spectrum 2 system, Fontus<sup>™</sup> liquid handling workstations, TotalSeq<sup>™</sup> reagents powered by BioLegend<sup>®</sup>, Dharmacon gene modulation reagents, and the Pin-point<sup>™</sup> Base Editing Platform , can provide you with the support needed to study different aspects of cancer, from genomics to precision medicine and beyond. With our commitment to innovation, combined with our shared knowledge and expertise, we are here to help fast track your progress in cancer research.

For research use only. Not for use in diagnostic procedures. BOOTH # 731

#### See our trusted brands

- AlphaLISA<sup>®</sup>
- BioLegend<sup>®</sup>
- Cellometer<sup>®</sup>
- Certimmune
- Dharmacon<sup>™</sup>
- EnVision<sup>®</sup> Nexus<sup>™</sup>
- Fontus<sup>™</sup>
- HTRF<sup>®</sup>
- IVIS<sup>®</sup> Spectrum
- Opera Phenix<sup>®</sup> Plus
- VICTOR<sup>®</sup> Nivo<sup>™</sup>



## **Featured Solutions**

# Experimental and molecular therapeutics

From discovery through manufacturing, creating safe and effective therapies is complex and expensive. Revvity enables scientists to develop and streamline workflows to help overcome these challenges.



Understanding how and why tumors proliferate and evolve is critical for identifying molecular targets for therapeutic or preventive intervention. Our reagent platforms and services allow researchers to explore genetic and mechanistic processes with ease.



## **Tumor Biology Solutions**

Analyzing a tumor's composition, organization, functionality, and microenvironment enables you to find routes for therapeutic manipulation and identify predictive biomarkers. Discover how our imaging and single-cell sequencing solutions can help you make your discoveries faster.



### **Clinical Research Solutions**

Advances in genomic sequencing and bioinformatics have revealed the enormous potential of cancer genomics. Our next-generation sequencing (NGS) technology solutions can facilitate the achievement of rapid, accurate sequencing of tumor-driving mutations as well as identifying biomarkers of disease progression.

## Posters

Microfluidic Capillary Electrophoresis Optimization of high throughput cfDNA and pDNA measurements for enabling Cancer Diagnostics and Gene Therapy Development

Alternative cell counting and viability detection using NexGreen/PI fluorescent stain on multiple low- and highthroughput image cytometry platforms

- Session Date and Time: Monday Apr 8, 2024 1:30 PM 5:00 PM
- Session Category: Chemistry
- Session Title: High-Throughput Screening and New Assay Technology
- Location: Poster Section 20
- Poster Board Number: 14
- Abstract Presentation Number: 3103

Developing a multiplex assay to monitor apoptosis and necrosis using the Cellaca® PLX Image Cytometer

- Session Date and Time: Sunday Apr 7, 2024 1:30 PM 5:00 PM
- Session Category: Molecular/Cellular Biology and Genetics
- Session Title: Apoptosis and FerroptosisLocation: Poster Section 15
- Poster Board Number: 12
- Abstract Presentation Number: 356

Characterization and comparison of hypoxia inducing factors on tumor growth and metastasis in 2D and 3D tumor models

Session Date and Time: Tuesday Apr 9, 2024 9:00 AM - 12:30 PM

- Session Category: Tumor Biology
- Session Title: Models to Study Immune Cells in the Tumor Microenvironment
- Location: Poster Section 10
- Poster Board Number: 23
- Abstract Presentation Number: 4221

Measuring apoptotic effects of EP4A1 and EP4A2 on Kuramochi with a highthroughput multiplex image cytometric method

- Session Date and Time: Monday Apr 8, 2024 1:30 PM 5:00 PM
- Session Category: Experimental and Molecular Therapeutics
- Session Title: Novel Antitumor Agents 4
- Location: Poster Section 26
- Poster Board Number: 11
- Abstract Presentation Number: 5930